El grupo de trabajo de Esófago-Estómago-Duodeno (EED) fue constituido en 1999 y desde entonces agrupa a los socios de AEG interesados en la fisiología y las enfermedades de los órganos mencionados, y recoge algunas otras patologías gastroenterológicas que pueden afectar a tramos más distales del tubo digestivo.
The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg)
María Caldas 1 , Ángeles Pérez-Aisa 2 , Bojan Tepes 3 , Alma Keco-Huerga 4 , Luis Bujanda 5 , Alfredo J Lucendo 6 , Luis Rodrigo 7 , Dino Vaira 8 , Luis Fernández-Salazar 9 , Jose M Huguet 10 , Jorge Pérez-Lasala 11 , Natasa Brglez Jurecic 12 , Galina Fadeenko 13 , Jesús Barrio 14 , Miguel Areia 15 , Juan Ortuño 16 , Rinaldo Pellicano 17 , Marcis Leja 18 , Javier Molina-Infante 19 , Pavel Bogomolov 20 , Sergey Alekseenko 21 , Manuel Domínguez-Cajal 22 , Judith Gómez-Camarero 23 , Vassiliki Ntouli 24 , Samuel J Martínez-Domínguez 25 , Rafael Ruiz-Zorrilla 26 , Oscar Núñez 27 , Aiman Silkanovna Sarsenbaeva 28 , Pedro Almela 29 , Perminder Phull 30 , Marta Espada 1 , Ignasi Puig 31 , Olga P Nyssen 1 , Francis Mégraud 32 , Colm O'Morain 33 , Javier P Gisbert 1 , the Hp-EuReg Investigators
Antibiotics (Basel). 2021 Aug 11;10(8):965. doi: 10.3390/antibiotics10080965.
Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1-1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59-0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4-2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3-5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.
Keywords: Helicobacter pylori; statins; treatment.